Adial Pharmaceuticals (ADIL) Interest Expenses (2017 - 2025)
Adial Pharmaceuticals (ADIL) posted Interest Expenses of $98730.0 for Q1 2025, down 42.15% sequentially from $170672.0 in Q4 2024, and up 2697.68% YoY from $3529.0 in Q1 2024.
Adial Pharmaceuticals (ADIL) Interest Expenses (2017 - 2025) Analysis & Trends
Adial Pharmaceuticals has reported Interest Expenses for 9 years, with the latest figure at $98730.0 in Q1 2025.
- Quarterly Interest Expenses rose 2697.68% year-over-year to $98730.0 in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $328090.0 (up 119.97% YoY) and the FY2025 annual result came in at $16.7 million, up 7.64% from the prior year.
- Interest Expenses slipped to $98730.0 in Q1 2025 per ADIL's latest filing, from $170672.0 in the prior quarter.
- Over five years, Interest Expenses peaked at $6.4 million in Q3 2021 and troughed at $129.0 in Q3 2022.
- A 5-year average of $662893.6 and a median of $65812.5 in 2023 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2021 and 2022: Interest Expenses surged 127747.33% in 2021, then sank 100.0% in 2022.
- Over 5 years, Interest Expenses stood at $22573.0 in 2021, then soared by 570.58% to $151371.0 in 2022, then plunged by 47.33% to $79724.0 in 2023, then surged by 114.08% to $170672.0 in 2024, then tumbled by 42.15% to $98730.0 in 2025.
- According to Business Quant data, Interest Expenses over the past three periods registered $98730.0, $170672.0, and $51901.0 for Q1 2025, Q4 2024, and Q3 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Adial Pharmaceuticals | 29.02 Mn | 29.02 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 98,730.00 |
| Mar 31, 2025 | 98,730.00 |
| Dec 31, 2024 | 170,672.00 |
| Dec 31, 2024 | 170,672.00 |
| Sep 30, 2024 | 51,901.00 |
| Sep 30, 2024 | 51,901.00 |
| Jun 30, 2024 | 6,787.00 |
| Jun 30, 2024 | 6,787.00 |
| Mar 31, 2024 | 3,529.00 |
| Mar 31, 2024 | 3,529.00 |
| Dec 31, 2023 | 79,724.00 |
| Dec 31, 2023 | 79,724.00 |
| Jun 30, 2023 | 51,901.00 |
| Jun 30, 2023 | 51,901.00 |
| Mar 31, 2023 | 14,000.00 |
| Mar 31, 2023 | 14,000.00 |
| Dec 31, 2022 | 151,371.00 |
| Dec 31, 2022 | 151,371.00 |
| Sep 30, 2022 | 129.00 |
| Sep 30, 2022 | 129.00 |